Richard Beger, FDA to Keynote at Metabolomics Conference on May 22-23, 2014 in Cambridge, MA

Cambridge, MA (PressExposure) April 04, 2014 -- Richard Beger, Director of the Biomarkers and Alternative Models Branch Division of Systems Biology at the National Center for Toxicological Research, FDA to give a keynote presentation on "Metabolomics of Acetaminophen Overdose in Rodents and Children" at the Metabolomics Conference - Advances & Applications in Human Disease to be held on May 22-23, 2014 in Cambridge, MA by GTC.

Drug-induced liver injury (DILI) is a reason many drugs fail in preclinical and early phase clinical testing. Even marketed drugs have such liabilities. The commonly used, OTC drug, acetaminophen (APAP) is a major cause of DILI. APAP-induced toxicity causes oxidative stress, ROS production, glutathione depletion, mitochondria dysfunction, disruption of energy metabolism, and altered immune response. Biofluid and tissue samples from preclinical APAP toxicity studies were analyzed by genomics, proteomics and metabolomics technologies to discover omics biomarkers of liver injury and recovery. Dr. Beger will discuss some of the metabolomics biomarkers found in the preclinical studies which are being evaluated in blood and urine samples from children that were accidentally overdosed with APAP. Omics evaluations of samples from a preclinical study of APAP toxicity identified changes related to fatty acid beta-oxidation metabolism and bile acids transportation. Evaluation of these biomarkers in clinical samples showed that elevations of bile acid metabolites occurred after liver injury in association with elevations of APAP-protein adducts. Importantly, bile acid metabolites and APAP-protein adducts were increased prior to the elevation of ALT, a standard clinical test for liver injury. The data suggest that bile acid metabolites and APAP-protein adducts are very sensitive indicators of liver toxicity due to APAP overdose.

Richard Beger, Ph.D., is the Director of Biomarkers and Alternative Models Branch at NCTR. The Biomarkers and Alternative Models Branch consists of metabolomics, proteomics and alternative models research teams that focus on discovering and evaluating biomarkers of disease and injury. He received his Ph.D. theoretical biophysics from Purdue University in 1991. He has been at the National Center for Toxicological Research (NCTR), US FDA, in Jefferson, AR for the last fifteen years. He has been a member of Society of Toxicology and Metabolomics Society. He is an author or co-author of over 105 publications including 6 book chapters. After arriving at the NCTR, he initiated research activities using NMR-based and MS-based metabolomics methods to identify non-invasive and tissue-based metabolic biomarkers of drug toxicity, drug efficacy, disease status, and individual susceptibility.

GTC's Metabolomics Conference program will focus on the clinical applications of metabolomics, such as advances in metabolite markers for use in personalized medicine, novel computational approaches for metabolic biomarker discovery, as well as developments in clinical assay standardization and qualification for the implementation of metabolite markers in drug discovery and clinical practice.

This conference is also part of the 2014 Drug Discovery, which consists of this conference and three other conferences:
1) Bioanalyitcal Sensors
2) GPCR Structure, Function and Drug Discovery
3) Single Cell Analysis

For more information, please visit

About GTC Conferences

GTC organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic institutions, government organizations and the financial community.

GTC (Global Technology Community), LLC, is a privately held company founded in 2002.

Press Release Source:

Press Release Submitted On: April 04, 2014 at 3:58 am
This article has been viewed 182529 time(s).